Becton, Dickinson and Company (NYSE:BDX) Updates FY 2024 Earnings Guidance

Becton, Dickinson and Company (NYSE:BDX) issued an update on its FY 2024 earnings guidance on Thursday. The company provided earnings per share guidance of 13.050-13.150 for the period, compared to the consensus earnings per share estimate of 13.040. The company issued revenue guidance of $20.1 billion-$20.2 billion, compared to the consensus revenue estimate of $20.2 billion.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on BDX. Evercore ISI lowered their price target on Becton, Dickinson and Company from $290.00 to $285.00 and set an outperform rating on the stock in a research report on Tuesday, July 2nd. StockNews.com downgraded Becton, Dickinson and Company from a buy rating to a hold rating in a report on Wednesday. Stifel Nicolaus upped their price objective on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a buy rating in a report on Friday, July 26th. Citigroup reduced their target price on shares of Becton, Dickinson and Company from $260.00 to $255.00 and set a neutral rating for the company in a report on Wednesday, July 10th. Finally, Barclays increased their price objective on Becton, Dickinson and Company from $305.00 to $312.00 and gave the stock an overweight rating in a research report on Monday, May 6th. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, Becton, Dickinson and Company presently has a consensus rating of Moderate Buy and a consensus price target of $280.13.

Becton, Dickinson and Company Stock Down 0.3 %

Shares of BDX opened at $241.07 on Thursday. Becton, Dickinson and Company has a one year low of $218.75 and a one year high of $284.48. The firm has a 50 day simple moving average of $232.53 and a two-hundred day simple moving average of $236.24. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.41 and a quick ratio of 0.97. The company has a market cap of $69.67 billion, a P/E ratio of 53.10, a P/E/G ratio of 2.08 and a beta of 0.42.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, May 2nd. The medical instruments supplier reported $3.17 EPS for the quarter, topping analysts’ consensus estimates of $2.97 by $0.20. The firm had revenue of $5.05 billion during the quarter, compared to analysts’ expectations of $5.04 billion. Becton, Dickinson and Company had a net margin of 6.76% and a return on equity of 13.90%. The business’s revenue for the quarter was up 4.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.86 earnings per share. Research analysts forecast that Becton, Dickinson and Company will post 13.04 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, September 30th. Stockholders of record on Monday, September 9th will be issued a dividend of $0.95 per share. The ex-dividend date is Monday, September 9th. This represents a $3.80 annualized dividend and a dividend yield of 1.58%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 83.70%.

Insider Activity at Becton, Dickinson and Company

In other news, EVP Roland Goette sold 3,300 shares of the business’s stock in a transaction dated Wednesday, May 15th. The stock was sold at an average price of $236.73, for a total transaction of $781,209.00. Following the sale, the executive vice president now directly owns 11,308 shares in the company, valued at $2,676,942.84. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other Becton, Dickinson and Company news, SVP Thomas J. Spoerel sold 300 shares of Becton, Dickinson and Company stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $239.31, for a total transaction of $71,793.00. Following the transaction, the senior vice president now directly owns 1,976 shares of the company’s stock, valued at approximately $472,876.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Roland Goette sold 3,300 shares of the stock in a transaction dated Wednesday, May 15th. The shares were sold at an average price of $236.73, for a total value of $781,209.00. Following the completion of the sale, the executive vice president now directly owns 11,308 shares of the company’s stock, valued at approximately $2,676,942.84. The disclosure for this sale can be found here. Insiders have sold a total of 6,900 shares of company stock valued at $1,634,112 in the last 90 days. 0.31% of the stock is owned by corporate insiders.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.